On this page
Halog
Halcinonide Cream · Cream
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Halcinonide | 1 mg/g | 310669 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 017556-001 | HALOG | CREAM | HALCINONIDE | Prescription | AB | RLD RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 41 | Manufacturing (CMC) | Approved | April 2, 2014 | Standard |
| Supplement | 38 | Manufacturing (CMC) | Approved | June 10, 2009 | N/A |
| Supplement | 34 | Labeling | Approved | September 29, 2004 | Standard |
| Supplement | 33 | Manufacturing (CMC) | Approved | June 29, 1990 | Standard |
| Supplement | 32 | Manufacturing (CMC) | Approved | June 27, 1989 | Standard |
| Supplement | 31 | Manufacturing (CMC) | Approved | March 23, 1989 | Standard |
| Supplement | 30 | Manufacturing (CMC) | Approved | November 3, 1987 | Standard |
| Supplement | 29 | Manufacturing (CMC) | Approved | May 27, 1986 | Standard |
| Supplement | 28 | Manufacturing (CMC) | Approved | April 22, 1986 | Standard |
| Supplement | 27 | Manufacturing (CMC) | Approved | July 30, 1985 | Standard |
| Supplement | 26 | Manufacturing (CMC) | Approved | January 28, 1985 | Standard |
| Supplement | 25 | Manufacturing (CMC) | Approved | May 24, 1984 | Standard |
| Supplement | 23 | Labeling | Approved | November 26, 1982 | — |
| Supplement | 24 | Manufacturing (CMC) | Approved | March 18, 1982 | Standard |
| Supplement | 22 | Manufacturing (CMC) | Approved | May 20, 1980 | Standard |
| Supplement | 21 | Manufacturing (CMC) | Approved | March 24, 1980 | Standard |
| Supplement | 19 | Labeling | Approved | February 13, 1980 | — |
| Supplement | 18 | Manufacturing (CMC) | Approved | February 2, 1979 | Standard |
| Supplement | 17 | Manufacturing (CMC) | Approved | January 10, 1979 | Standard |
| Supplement | 16 | Labeling | Approved | June 7, 1978 | — |
| Supplement | 15 | Manufacturing (CMC) | Approved | June 7, 1978 | Standard |
| Supplement | 13 | Manufacturing (CMC) | Approved | April 19, 1978 | Standard |
| Supplement | 12 | Manufacturing (CMC) | Approved | January 9, 1978 | Standard |
| Supplement | 11 | Manufacturing (CMC) | Approved | August 24, 1977 | Standard |
| Supplement | 8 | Labeling | Approved | March 8, 1977 | — |
| Supplement | 7 | Manufacturing (CMC) | Approved | February 9, 1976 | Standard |
| Supplement | 3 | Manufacturing (CMC) | Approved | May 7, 1975 | Standard |
| Supplement | 4 | Labeling | Approved | April 4, 1975 | — |
| Original application | 1 | Type 1 - New Molecular Entity | Approved | November 27, 1974 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260115). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE HALOG (Halcinonide Cream, USP) 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION SECTION Apply the 0.1% HALOG (Halcinonide Cream, USP) to the affected area two to three times daily. Rub in gently. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Gently rub a small amount of cream into the lesion until it disappears. Reapply the preparation leaving a thin coating on the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the non-porous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply HALOG under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional cream should be applied, without occlusion, during the day. Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Description
openFDA Drug LabelingDESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. The steroids in this class include halcinonide. Halcinonide, USP is designated chemically as 21-Chloro-9-fluoro-11β, 16α, 17-trihydroxypregn-4-ene-3,20-dione cyclic 16,17-acetal with acetone. Graphic formula: Each gram of 0.1% HALOG (Halcinonide Cream, USP) contains 1 mg halcinonide, USP in a specially formulated cream base consisting of cetyl alcohol, dimethicone 350, glyceryl monostearate, isopropyl palmitate, polysorbate 60, propylene glycol, purified water, and titanium dioxide. struture
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS: General ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED HALOG ® (Halcinonide Cream, USP) 0.1% is smooth, soft homogeneous white to off-white cream, essentially free of foreign matter and is supplied as: NDC 10631-094-30 Tubes containing 60 g NDC 10631-094-76 Jar containing 216 g NDC 10631-094-71 Carton containing 240 g (4 tubes of 60g)
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: HALCINONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 64950-126-06 | 64950-126 | Genus Lifesciences Inc. | 1 TUBE in 1 CARTON (64950-126-06) / 60 g in 1 TUBE | January 13, 2026 |
| 10631-094-20 | 10631-094 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (10631-094-20) / 30 g in 1 TUBE | February 10, 2009 |
| 10631-094-30 | 10631-094 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (10631-094-30) / 60 g in 1 TUBE | February 10, 2009 |
| 10631-094-71 | 10631-094 | Sun Pharmaceutical Industries, Inc. | 4 TUBE in 1 CARTON (10631-094-71) / 60 g in 1 TUBE | July 2, 2018 |
| 10631-094-76 | 10631-094 | Sun Pharmaceutical Industries, Inc. | 216 g in 1 JAR (10631-094-76) | February 10, 2009 |
| 64950-126 | 64950-126 | Genus Lifesciences Inc. | — | January 13, 2026 |
| 10631-094 | 10631-094 | Sun Pharmaceutical Industries, Inc. | — | February 10, 2009 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.